JP7399898B2 - ＰｑｓＲインバースアゴニスト - Google Patents

ＰｑｓＲインバースアゴニスト Download PDF

Info

Publication number
JP7399898B2
JP7399898B2 JP2020573396A JP2020573396A JP7399898B2 JP 7399898 B2 JP7399898 B2 JP 7399898B2 JP 2020573396 A JP2020573396 A JP 2020573396A JP 2020573396 A JP2020573396 A JP 2020573396A JP 7399898 B2 JP7399898 B2 JP 7399898B2
Authority
JP
Japan
Prior art keywords
group
trifluoromethyl
methyl
pyridin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529203A5 (https=
JP2021529203A (ja
JPWO2020007938A5 (https=
Inventor
エス．アー． アフマド，アフマド
エンプティング，マーティン
ハメド，ムスタファ
ヴェー． ハルトマン，ロルフ
ホーペンタール，イェルク
ヘスターカンプ，トーマス
アー．エム． カマル，アフマド
カー． マウラー，クリスティーネ
レーリヒ，テレーザ
シュッツ，クリスティアン
ヤヤーウイ，サミール
ツェンダー，ミハエル
Original Assignee
ヘルムホルツ－ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ－ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー filed Critical ヘルムホルツ－ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー
Publication of JP2021529203A publication Critical patent/JP2021529203A/ja
Publication of JP2021529203A5 publication Critical patent/JP2021529203A5/ja
Publication of JPWO2020007938A5 publication Critical patent/JPWO2020007938A5/ja
Application granted granted Critical
Publication of JP7399898B2 publication Critical patent/JP7399898B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020573396A 2018-07-03 2019-07-03 ＰｑｓＲインバースアゴニスト Active JP7399898B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18181475 2018-07-03
EP18181475.7 2018-07-03
PCT/EP2019/067899 WO2020007938A1 (en) 2018-07-03 2019-07-03 PqsR INVERSE AGONISTS

Publications (4)

Publication Number Publication Date
JP2021529203A JP2021529203A (ja) 2021-10-28
JP2021529203A5 JP2021529203A5 (https=) 2022-07-04
JPWO2020007938A5 JPWO2020007938A5 (https=) 2022-07-04
JP7399898B2 true JP7399898B2 (ja) 2023-12-18

Family

ID=62846069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573396A Active JP7399898B2 (ja) 2018-07-03 2019-07-03 ＰｑｓＲインバースアゴニスト

Country Status (6)

Country Link
US (1) US11883387B2 (https=)
EP (1) EP3818045A1 (https=)
JP (1) JP7399898B2 (https=)
AU (1) AU2019297409B2 (https=)
CA (1) CA3103351A1 (https=)
WO (1) WO2020007938A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3164264A1 (en) * 2020-01-02 2021-07-08 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Novel pqsr inverse agonists
US12528783B2 (en) 2020-01-02 2026-01-20 Helmholtz-Zentrum Fur Infektionsforschung Gmbh PqsR inverse agonists
WO2024186827A2 (en) * 2023-03-06 2024-09-12 The Regents Of The University Of California Novel host-directed therapeutic agent for the treatment of infectious diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
CN108003151A (zh) 2016-10-27 2018-05-08 湖南化工研究院有限公司 N-杂芳基甲基嘧啶胺类化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877940B2 (en) 2011-02-22 2014-11-04 Institut National De La Recherche Scientifique Antibiotic tolerance inhibitors
US9643933B2 (en) 2013-04-23 2017-05-09 The General Hospital Corporation Compounds useful as antibiotic tolerance inhibitors
WO2016007837A1 (en) 2014-07-11 2016-01-14 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors
WO2016040764A1 (en) 2014-09-12 2016-03-17 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl n-benzimidazoles and analogs as antibiotic tolerance inhibitors
WO2016112088A1 (en) 2015-01-06 2016-07-14 Spero Therapeutics, Inc. Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
CN108003151A (zh) 2016-10-27 2018-05-08 湖南化工研究院有限公司 N-杂芳基甲基嘧啶胺类化合物及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＤＡＴＡＢＡＳＥ REGISTRY ｏｎ STN，RN 1546402-30-5 REGISTRY Entered STN: 17 Feb 2014

Also Published As

Publication number Publication date
CA3103351A1 (en) 2020-01-09
AU2019297409B2 (en) 2022-12-01
WO2020007938A1 (en) 2020-01-09
EP3818045A1 (en) 2021-05-12
JP2021529203A (ja) 2021-10-28
US11883387B2 (en) 2024-01-30
AU2019297409A1 (en) 2021-01-07
US20210353606A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
CA2702647C (en) Thiopyrimidine-based compounds and uses thereof
EP1562911B1 (en) Compositions useful as inhibitors of jak and other protein kinases
US9242977B2 (en) Trk-inhibiting compound
JP4688498B2 (ja) Ｊａｋインヒビターとしてのヘテロアリール−ピリミジン誘導体
KR20090125779A (ko) 브라디키닌 ｂ2 수용체 조절제로서 8-옥시-퀴놀린 유도체
JP2008503492A (ja) Ｒｈｏ−キナーゼの新規阻害剤
JP2010537967A (ja) 癌及び乾癬の治療に有用な複素環式アミド
JP7399898B2 (ja) ＰｑｓＲインバースアゴニスト
JP2014509616A (ja) 治療用イミダゾ［１，２−ａ］ピリジン化合物
CA3144506A1 (en) Substituted amino heteroaryl derivatives and compositions thereof usefule as antifibrotic compounds
US11548900B2 (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
KR20180105801A (ko) TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체 및 이를 포함하는 약제학적 조성물
US20180305331A1 (en) Pyridone derivatives and their use as kinase inhibitors
WO2020046975A1 (en) Methods of treating neurodegenerative diseases
WO2011057892A1 (en) 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivates as hif-inhibitors for the treatment of cancer and inflammatory diseases
JP7421655B2 (ja) 新規なＰｑｓＲインバースアゴニスト
US7119109B2 (en) Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
EP4085054B1 (en) New pqsr inverse agonists
US10472326B2 (en) PQSR modulators
EP1572686A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
MXPA06008833A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231206

R150 Certificate of patent or registration of utility model

Ref document number: 7399898

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150